ArticleNature medicine2020
COVID-19 clinical trials: learning from exceptions in the research chaos.
Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials.The Lancet. Respiratory medicine · 2023Pooled it
- A rapid review of community engagement and informed consent processes for adaptive platform trials and alternative design trials for public health emergencies.Wellcome open research · 2023Pooled it
- Randomized controlled trials in patients with COVID-19: a systematic review and critical appraisal.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Pooled it
- Don't Let the Evidence Die: From Rapid to Living Reviews, Experiences From the Global South.Campbell systematic reviews · 2026Article
- A scoping review of randomized controlled trials in the early phase of the COVID-19 pandemic: country-level research response to COVID-19 therapeutics and vaccines.BMC infectious diseases · 2026Article
- Increasing research capacity in Canadian community hospitals: an intrinsic descriptive case study.Health research policy and systems · 2025Article
- Qualitative evaluation to improve participant engagement and retention in remote COVID-19 treatment trials.Discover public health · 2025Article
- COVID-19 clinical trial participation and awareness in Texas.Human vaccines & immunotherapeutics · 2024Article
- Clinical trials and their impact on policy during COVID-19: a review.Wellcome open research · 2024Review
- Identification of the ideal recruitment situation in pandemic research: learning from the RECOVERY trial in Northern England: a qualitative study.BMJ leader · 2023Article
- Therapeutic strategies for COVID-19: progress and lessons learned.Nature reviews. Drug discovery · 2023Review
- Stopping epidemics when and where they occur.Lancet (London, England) · 2023Article
- Prolific non-research authors in high impact scientific journals: meta-research study.Scientometrics · 2023Article
- Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial.Nature communications · 2022Article
- Lessons from a large-scale COVID-19 vaccine trial.The Journal of clinical investigation · 2022Article
- Ending the tuberculosis syndemic: is COVID-19 the (in)convenient scapegoat for poor progress?The Lancet. Respiratory medicine · 2022Article
- Research lessons during the COVID-19 pandemic: collecting longitudinal physical and mental health outcomes.Archives of public health = Archives belges de sante publique · 2022Article
- CNN-based framework for classifying temporal relations with question encoder.International journal on digital libraries · 2022Article
- Technology-assisted adaptive recruitment strategy for a large nation-wide COVID-19 vaccine immunogenicity study in Brunei.Frontiers in public health · 2022Article
- Clinical Evidence Informing Treatment Guidelines on Repurposed Drugs for Hospitalized Patients During the Early COVID-19 Pandemic: Corticosteroids, Anticoagulants, (Hydroxy)chloroquine.Frontiers in public health · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
32963376What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.